HomeInsightsStock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Last Updated on: Apr 30, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1558 as of 30 Apr 09:44.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 years.
  • The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73% The revenue of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 8535 crore as compare to the Sep '24 revenue of ₹ 8351 crore. This represent the growth of 2.2%.
  • The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47% The ebitda of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 2427 crore as compare to the Sep '24 ebitda of ₹ 2390 crore. This represent the growth of 1.56%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1404 crore over 7 quarters. This represents a CAGR of -0.03% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys announces cessation of subsidiary in Louisiana

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successf...

Read more

24 Mar 2025 13:48

News

Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 M...

Read more

22 Mar 2025 11:01

News

Dr. Reddy's recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy's Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75%...

Read more

13 Mar 2025 18:46

News

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powe...

Read more

06 Mar 2025 19:16

News

Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility

The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed ...

Read more

27 Feb 2025 09:57

News

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fu...

Read more

14 Feb 2025 18:24

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Cipla Ltd or Dr Reddys Laboratories Ltd?

Market cap of Cipla Ltd is 124,457 Cr while Market cap of Dr Reddys Laboratories Ltd is 98,152 Cr

What are the key factors driving the stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Dr Reddys Laboratories Ltd?

As of April 30, 2025, the Cipla Ltd stock price is INR ₹1541.0. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1176.25.

How do dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions